Core Viewpoint - The stock of *ST长药 experienced an abnormal price fluctuation, with a cumulative increase of 46.41% over two consecutive trading days on January 20-21, 2026, despite the absence of any undisclosed significant matters [1] Financial Performance - The company reported a significant decline in revenue, with figures dropping from 1.615 billion yuan in 2022 to an estimated 112 million yuan in 2024 [1] - The company is projected to have negative net assets for the years 2024-2025 [1] Legal and Financial Risks - The company is currently involved in 153 lawsuits, with a total amount in dispute of 1.932 billion yuan [1] - The company has interest-bearing liabilities amounting to 1.106 billion yuan, with overdue debts of 390 million yuan [1] Stockholder Activity - There has been no trading activity reported by the controlling shareholder or actual controller of the company [1]
*ST长药：股价异常波动，面临多项退市及经营风险
Xin Lang Cai Jing·2026-01-21 11:53